Sophia Genetics SA Form 4 insider transactions

SOPHIA GENETICS SA reports an amendment to a Form 4 filing, correcting beneficial ownership of ordinary shares and detailing a new share option grant.

George Cardoza, Chief Financial Officer of SOPHiA GENETICS SA, filed an amended Form 4 to correct previously reported beneficial ownership of ordinary shares.

SOPHIA GENETICS SA reports an amendment to a Form 4 filing detailing equity transactions and beneficial ownership for CEO Jurgi Camblong.

SOPHiA GENETICS SA files an amended Form 4 detailing a correction in beneficial ownership of ordinary shares and an update on stock options granted to Chief Medical Officer Philippe Menu.

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert files an amended Form 4 to correct previously reported beneficial ownership of ordinary shares and details a new share option grant.

SOPHiA GENETICS SA files an amended Form 4 to correct previously reported beneficial ownership of ordinary shares and detail a new restricted stock unit grant and share option.

SOPHIA GENETICS SA files an amended Form 4 detailing a restricted stock unit grant and correcting previous ownership figures for Chief Scientific Officer Zhenyu Xu.

SOPHiA GENETICS SA reports an amendment to a Form 4 filing, detailing an RSU grant and share option for Chief Technology Officer Abhimanyu Verma, with updated beneficial ownership figures.

SOPHiA GENETICS SA reports that Chief Technology Officer Abhimanyu Verma was granted restricted stock units and stock options on April 2, 2026.

SOPHIA GENETICS SA reports significant equity grants to President Ross Muken, including restricted stock units and share options, with vesting schedules extending to 2030.

SOPHiA GENETICS SA reports a significant equity grant to Chief Medical Officer Philippe Menu, comprising restricted stock units and share options.

SOPHIA GENETICS SA reports on equity grants and options awarded to Chief Scientific Officer Zhenyu Xu, detailing vesting schedules and ownership.

SOPHiA GENETICS SA reports that CEO Jurgi Camblong was granted restricted stock units and stock options.

SOPHiA GENETICS SA reports on equity awards granted to Chief Sales Officer Kevin Puylaert, including restricted stock units and share options.

SOPHIA GENETICS SA announces equity awards to Chief Financial Officer George Cardoza, including restricted stock units and stock options, with vesting schedules extending to 2030.

SOPHIA GENETICS SA reports a Form 4 filing detailing equity awards to Chief People Officer Manuela Valente, including restricted stock units and share options.

SOPHiA GENETICS SA reports on equity awards granted to Chief Legal Officer Daan van Well, including restricted stock units and share options.

SOPHiA GENETICS Chief Sales Officer Kevin Puylaert sold 3 ordinary shares to cover tax obligations related to restricted stock unit vesting.

SOPHiA GENETICS' Chief Legal Officer, Daan Van Well, sold 684 ordinary shares for $4.7865 per share to cover tax liabilities from RSU vesting.

SOPHiA GENETICS CEO Jurgi Camblong sold 4,486 ordinary shares to cover tax liabilities from restricted stock unit vesting, as per a 10b5-1 plan.

SOPHiA GENETICS' Chief Medical Officer, Philippe Menu, sold 608 ordinary shares on March 19, 2026, at a weighted average price of $4.7908 to cover tax liabilities from restricted stock unit vesting.

SOPHiA GENETICS' Chief Scientific Officer, Zhenyu Xu, sold 608 ordinary shares to cover tax liabilities from restricted stock unit vesting, executed under a 10b5-1 plan.

SOPHiA GENETICS' Chief People Officer, Manuela Valente, sold 380 ordinary shares to cover tax liabilities from restricted stock unit vesting, executed under a Rule 10b5-1 plan.

SOPHiA GENETICS President Ross Muken sold 1,183 ordinary shares on March 19, 2026, at a weighted average price of $4.7937 to cover tax obligations from RSU vesting.

SOPHiA GENETICS' Chief Sales Officer, Kevin Puylaert, reported a future 'sell to cover' transaction of 33 ordinary shares for tax obligations related to RSU vesting in March 2026.

SOPHiA GENETICS Chief Financial Officer George Cardoza sold 774 ordinary shares to cover tax liabilities from restricted stock unit vesting.